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OBJECTIVES: Renal cell carcinoma (RCC) is the most common renal tumor and
accounts for 2 to 3% of all adult malignancies. Up to 30% of patients with renal-cell
carcinoma present withmetastatic disease. The aim of the study was to assess the
cost-effectiveness of first-line medications for patients with metastatic RCC from
the payer‘s perspective.METHODS: A Markov model was developed using 6-week
cycles for evaluating the cost-effectiveness of fourmRCC first-line therapies: Inter-
feron- (3million units (MU)/day 3 times-per-week for first week; 6MU/day 3 times-
per-week for second week, 9MU/day 3 times per-week third week onward),
sunitinib (50mg/day 4 weeks ON  2 weeks OFF), sorafenib (400mg/twice-a-day)
and bevacizumab plus Interferon  (10mg/kg/bi-weekly  9MU 3 times-per-week
every 3weeks). Themodel had a 10-year time horizon. The fourmodel stageswere:
No progression, progression, best supportive care and death. Effectiveness data
were obtained through a systematic review, resource utilization were collected
from a Colombian Delphi Panel, and costs includedwere retrieved fromColombian
tariff manual (SOAT). Effectiveness was measured by progression-free life years
(PFLY) and life-years gained (LYG). Costs and outcomes were discounted with a 3%
annual rate. Univariate sensitivity analysis was developed. RESULTS: Sunitinib
showed higher overall mean costs per patient (US$ 5,215.48) compared to inter-
feron; while comparing against sorafenib and bevacizumab  interferon sunitinib
costs per patient revealed to be lower in US$12,946.01 and US$ 102,780.16 respec-
tively. Sunitinib had the higher effectiveness RESULTS: 1.35 PFLY, 2.9 LYG and 1.87
QALY. Incremental cost-effectiveness analysis shows sunitinib is cost-saving com-
pared to sorafenib and to the combination of bevacizumab  interferon, and com-
pared to monotherapy with interferon the incremental cost-effectiveness ratio
(ICER) per LYG for sunitinib was US$12,099, per PFLY was US$8,381 and per QALY
was US$14,901. CONCLUSIONS: This analysis indicates that sunitinib represents
the most cost-effective option for first-line mRCC treatment in Colombia.
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OBJECTIVES: To compare the costs and the effectiveness of three strategies against
Cervical Cancer (CC): (i) Screening for CC; (ii) Bivalent vaccine (BV) for HPV 16/18
along with screening and (iii) Quadrivalent Vaccine (QV) for HPV 6/11/16/18 along
with screening. METHODS: A Markov model was designed to simulate natural
history of disease in women, since 12 –vaccination-until 85 years old. Transition
probabilities were selected or adjusted to correspond to HPV distribution profile
amongColombianwomen.A systematic reviewwas performed to obtain efficacy of
vaccines and screening. Societal perspective was used. The costs analysis included
medical and non-medical such as transport, patient/ companion time and care at
home. Effectiveness was measured in number of life years saved (LYS). Since QV
protects againstHPV 6/11which causedGenitalWarts, the impact of this additional
effect is measured in the saved money by the reduction in treatment of GW cases.
RESULTS: BV was found to be the most costly and also the most effective strategy,
followed by QV and finally screening alone. QV resulted to have an incremental
cost- effectiveness ratio of US 2232 per LYS; BV compared with QV had an incre-
mental cost-effectiveness ratio of US 7335. Per 100.000 women vaccinated with QV,
8252 LYS are gained over screening alone. For BV only 348 LYSwere gained over QV.
According to sensibility analysis, results were not affected by vaccines effective-
ness but changes in current price of them could modify cost-effectiveness profile.
With a 12% price reduction, BV dominate over quadrivalent vaccine.
CONCLUSIONS: Both vaccines resulted to be similar in costs an also in effective-
ness for Colombian context. HPV vaccination is farmore effective but also farmore
expensive than screening. HPV vaccination is recommended in Colombia but price
considerations should be taken into account.
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OBJECTIVES: Cetuximab, a chimeric monoclonal antibody, improved the overall
survival and progression free survival of chemorefractory metastatic colorectal
cancer (mCRC) KRAS wild (unmutated) type patients in the National Cancer Insti-
tute of Canada Clinical Trials Group (NCIC CTG) CO.17 study. The objective of our
study was to conduct the cost-effectiveness analysis of cetuximab plus best sup-
portive care versus best supportive care alone in KRAS wild type mCRC patients.
METHODS: AMarkov cohort simulation model was used to simulate therapy costs
and effectiveness from the US societal perspective. All estimates of costs and ef-
fectiveness were obtained from the literature. The cost-effectiveness ratio was
reported as incremental cost per quality-adjusted life-year (QALY) gained. A life
time horizon was used. Base case costs and QALYs were discounted at an annual
rate of 3%. All costs were adjusted to 2011 US dollars. One-way and probabilistic
sensitivity analyses were used to determine the robustness of the model’s results
using @Risk. Themodel was developed using Microsoft Excel. RESULTS: The incre-
mental cost with cetuximab comparedwith best supportive care alonewas $93,934
and the mean gains in quality adjusted survival were 0.30 QALYS. This resulted in
base case ICER of $313,113 perQALY gained. The resultswere highly sensitive to the
cost of cetuximab and health state utility values. CONCLUSIONS: The incremental
cost effectiveness ratio of $313,113 per QALY gained for cetuximab plus BSC com-
pared with BSC alone suggests that cetuximab is not cost effective in KRAS wild
type patients with metastatic colorectal cancer even with a willingness-to-pay
cut-off threshold of $120-$150,000 per QALY gained.
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OBJECTIVES: To describe outcomes and economic impact of hypomethylating
therapy (Decitabine/Azacitidine) compared to transfusion therapy in adult patients
with Myelodysplastic syndrome (MDS) non-candidates to transplant. METHODS:
Was building a Markov Model simulating the disease with 6 stages; Myelodysplas-
tic syndrome in treatment, Complete PartialHematologic Response (CPHR),
transfusion independent, transfusion dependent, Myeloid Leukemia and Death.
Every medication was compared with each control group in two different simula-
tions because the characteristics of every control group were different. We were
interested in finding the incremental values in outcomes and costs of each treat-
ment. Our case base was an adult patient with MDS non-candidate to transplant.
The Temporal Horizon was 1 year, perspective of insurer and mortality avoided
progression free disease (PFD) and survival as outcomes. The statistics inputs of the
model for the transitions were the Kapplan-Meier curves of Kantarjian H and Fe-
naux P papers. Were used direct costs from a private hospital in Bogota, Colombia
and government prices according regulation laws. RESULTS: The simulation proj-
ect incremental effectiveness for both hypometilants compared with transfu-
sion therapy. In terms of CPHR was 40% for Decitabine and 28% for Azaciti-
dine, in PFD was 73% for Decitabine and 76% for Azacitidine and survival was
50% for Decitabine and 37% for Azacitidine. Compared with transfusion therapy
Decitabine was a cost-saving alternative (better results with lower costs) vs.
cost-effectiveness for Azacitidine (better results with higher costs).
CONCLUSIONS: In Colombia the hypomethylant therapy with Decitabine is a cost-
saving alternative compared with transfusion therapy.
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OBJECTIVES:Abiraterone acetate (AA), a selective androgen biosynthesis inhibitor,
blocks the action of CYP17, thereby inhibiting adrenal and intratumoral androgen
synthesis. In a preplanned interim analysis of the Phase 3 trial COU-AA-301, AA
plus prednisone (P) showed a significant overall survival (OS) benefit of 3.9 months
vs placebo plus P (de Bono, NEJM 2011). A preplanned and updated analysis showed
that the improvement in median OS increased from 3.9 months to 4.6 months
(HR  0.74) (Scher, ASCO 2011). The purpose of this study was to evaluate the
cost-effectiveness of AA compared to cabazitaxel. METHODS: A survival-based
decision analysis model was developed incorporating 3 health states: progression-
free survival, post-progression survival, and OS (indirect comparison). Assuming
mitoxantrone (M)  P versus P equivalence, a cost-effectiveness model was popu-
latedwith data from two placebo-controlled randomized clinical trials inwhich: (1)
AAwas an add-on to P (de Bono, NEJM 2011), and 2) cabazitaxel or Mwas an add-on
to P (de Bono, Lancet 2010) in patients with metastatic castrate-resistant prostate
cancer post-docetaxel. Resource utilization and costs reflected Swedish treatment
conditions within a broad societal perspective. Drug costs per 3-week-model-cycle
were $3180 (€2300) and $6730 (€4860) for AA and cabazitaxel, respectively.
RESULTS: Total costs per patient were $103,100 (€74,400) and $104,600 (€75,500) for
AA and cabazitaxel, respectively. Quality-adjusted life years (QALYs) were 0.94 and
0.83 for AA and cabazitaxel, respectively. CONCLUSIONS: The results show that AA
treatment is superior to cabazitaxel in cost per QALY gained. AA appears to provide
an OS benefit, compared to cabazitaxel, with a highly manageable and benign
safety profile. Adverse events affect both costs associated with taking a given drug
as well as health-related quality-of-life of patients receiving treatment.
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OBJECTIVES: In the ZO-FAST trial, postmenopausal women with early breast can-
cer (pmBCa) and a bonemineral density (BMD) T-score–2 and receiving adjuvant
Letrozole (2.5 mg/day) were randomized to either immediate ZOL (4 mg/6 months)
treatment (“Upfront ZOL”) or to the same therapy but only when BMD T-score
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